From promise to practice: a guide to developing pooled procurement mechanisms for medicines and vaccines.

J Pharm Policy Pract

Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Oudlaan 50, 3062 PA, Rotterdam, The Netherlands.

Published: June 2023

Introduction: Buyers of medicines and vaccines are increasingly interested in pooling their procurement to improve access to affordable and quality-assured health commodities. However, the academic literature has provided no detailed description of how pooled procurement mechanisms are set up and develop over time. These insights are valuable as it increases our understanding of implementing and operating pooled procurement mechanisms successfully. Therefore, the aim of this paper is twofold. First, to explore how such mechanisms evolve over time. Second, to clarify the work that is needed to set up and sustain a pooled procurement mechanism. These findings have been translated into our Pooled Procurement Guidance document.

Methods: This qualitative study draws upon theoretical insights from organizational life cycles, collaborative and network governance, semi-structured interviews with procurement experts and academic and grey literature documents on pooled procurement of medicines and vaccines.

Results: We identified four general developmental stages of pooled procurement mechanisms: promise, creation, early operational and mature. The promise stage is characterized by initiating engagement between participating actors, while they try to convert their perceived problem(s) or opportunities into a shared vision. The creation stage is where the participating actors formalize and design the mechanism through consensus-building, articulation of a shared plan, and mobilize resources to put the shared plan into action. The early operational stage is where the shared plan is being executed. The newly established or appointed procurement organization is required to learn fast from experience while showing flexibility to the changing needs of buyers and suppliers. Once operations are routinized, the mechanism enters the mature stage. During this stage, the pooled procurement organization develops into a trusted player that provides sufficient incentives for all actors involved. Importantly, pooled procurement mechanisms can stagnate or turn inactive at any time during the developmental process when alignment between actors is threatened.

Conclusions: Pooled procurement mechanisms evolve over time. Setting up such mechanisms is a collaborative process that relies on intentional efforts by key actors involved. To increase the lifespan of pooled procurement mechanisms, key actors need to sustain a relative alignment of goals, needs, motivations and purpose of the mechanism throughout its entire life cycle.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264874PMC
http://dx.doi.org/10.1186/s40545-023-00574-9DOI Listing

Publication Analysis

Top Keywords

pooled procurement
44
procurement mechanisms
28
procurement
14
shared plan
12
pooled
11
mechanisms
9
medicines vaccines
8
mechanisms evolve
8
evolve time
8
early operational
8

Similar Publications

Background: As China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern. Biosimilars, potentially lower-cost versions of biologics, may improve access to more affordable yet comparably effective treatments. Encouragingly, China launched its abbreviated biosimilar pathway in 2015, and since then, a large number of biosimilars have been approved.

View Article and Find Full Text PDF
Article Synopsis
  • - The paper highlights the increasing difficulty in maintaining access to both old and new antibiotics, leading to negative impacts on healthcare and a rise in antibiotic resistance due to the use of less effective alternatives.
  • - It identifies four types of antibiotic unavailability—short-term shortages, long-term shortages, deregistrations, and lack of registration—explaining their causes, consequences, and potential solutions, supported by examples from Norway, Romania, and Ethiopia.
  • - Understanding the specific type of antibiotic unavailability is crucial for finding effective solutions, as strategies like stockpiling may only be effective for certain circumstances and won't address every issue related to access.
View Article and Find Full Text PDF

Objective: To generate evidence about changes in the research and development (R&D) investment of Chinese chemical pharmaceutical companies before and after the implementation of the national pooled procurement, to respond to the concerns that significant price reductions might negatively affect R&D investment, and to facilitate the evidence-based decision-making for improvement of the national pooled procurement.

Methods: This retrospective study employed the fixed-effects models with robust SEs to analyse the changes in R&D investment intensities of 76 A-share listed Chinese chemical pharmaceutical companies before and after the procurement implementation in 2019. The analyses were based on a panel data set between 2013 and 2022.

View Article and Find Full Text PDF

Various directed evolution methods exist that seek to procure bacteriophages with expanded host ranges, typically targeting phage-resistant or non-permissive bacterial hosts. The general premise of these methods involves propagating phage(s) on multiple bacterial hosts, pooling the lysate, and repeating this process until phage(s) can form plaques on the target host(s). In theory, this produces a lysate containing input phages and their evolved phage progeny.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the growth of biosimilars in China, focusing on trastuzumab, aiming to understand its national uptake and the influencing factors.
  • Utilizing interrupted time series analysis and a latent class trajectory model, the research analyzes data from March 2018 to February 2023, revealing trends in biosimilar and originator consumption post-introduction of the first biosimilar.
  • Findings indicate a moderate national biosimilar penetration of 27% by February 2023, with faster uptake in regions with specific socioeconomic characteristics, such as better insurance coverage and lower GDP per capita.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!